Ofatumumab versus Teriflunomide in Multiple Sclerosis

In two double-blind, double-dummy, phase 3 trials (n=946 ofatumumab [OF]; 936 teriflunomide [TF]), OF was linked to lower annualised relapse rates than TF (0.11 and 0.22, respectively, in trial 1 [p<0.001] and 0.10 and 0.25 in trial 2; [p<0.001]; median follow-up 1.6 years).

SPS commentary:

Teriflunomide is an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. It was filed for approval in EU in Feb 2020 for treatment of relapsing-remitting multiple sclerosis.


New England Journal of Medicine